Home › Graft-Versus-Host Disease › NCT06450925

Vitamin A Supplementation in Allogeneic Stem Cell Transplantation.

A Randomized Double Blinded Trial of Vitamin A Supplementation in Allogeneic Stem Cell Transplantation.

Who can join

Ages 18 and older · All sexes

Inclusion Criteria:

* Be 18 years of age or older
* Be scheduled for allogeneic stem cell transplant.
* Have a vitamin A level \< upper limit of normal for age.
* Be able to tolerate enteral vitamin dose administration.
* Have a total bilirubin level \< 1.5x ULN and an AST and/or ALT\< 3xULN for age
* Receiving PBSCs as stem cell graft

Exclusion Criteria:

* Ongoing raised intracranial pressure (see appendix D for definition of raised intracranial pressure)
* Liver cirrhosis (see appendix C for definition of liver cirrhosis)
* Patients will be excluded if they are currently pregnant.
* Patients will be excluded if they have a fish (not shellfish) allergy.

About the study

The investigators hypothesize that single oral high dose supplementation with vitamin A will reduce the incidence of moderate-severe chronic graft-versus-host disease (GVHD) compared with placebo.

What is being tested

• Vitamin A (drug)
• Placebo (other)

Sponsor: Children's Hospital Medical Center, Cincinnati · Participants: 190 · Started: Mar 25, 2025

Contact the study team

• Celeste Dourson, MS, CCRP · Phone: 513-636-7679

Official record on ClinicalTrials.gov — NCT06450925

Locations in the U.S.

Conditions

• Graft-Versus-Host Disease
• Vitamin D Deficiency

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.